News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

|Videos|December 13, 2022

Importance of Clinical Trial Data, Disease Control, and QoL in Atopic Dermatitis Management

Author(s)Raj Chovatiya, MD, PhD, MSCI, Neal Bhatia, MD

Raj Chovatiya, M.D., Ph.D. and Neal Bhatia, MD comment on the importance of assessing a treatment’s available clinical trial data, ability to control disease severity, and QoL impacts when assessing atopic dermatitis treatment options.

Episodes in this series

EP. 1 Expert Perspectives on the Rapid Expansion of Atopic Dermatitis Treatments

EP. 1 Expert Perspectives on the Rapid Expansion of Atopic Dermatitis Treatments

EP. 2 Atopic Dermatitis Treatment Biological Targets

EP. 2 Atopic Dermatitis Treatment Biological Targets

EP. 3 Use of JAK Inhibitors in Clinical Practice

EP. 3 Use of JAK Inhibitors in Clinical Practice

EP. 4 Importance of Clinical Trial Data, Disease Control, and QoL in Atopic Dermatitis Management

EP. 4 Importance of Clinical Trial Data, Disease Control, and QoL in Atopic Dermatitis Management

EP. 5 Final Thoughts for Atopic Dermatitis Treatment

EP. 5 Final Thoughts for Atopic Dermatitis Treatment

EP. 6 Frontline Forum Part 1: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 6 Frontline Forum Part 1: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 7 Frontline Forum Part 2: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 7 Frontline Forum Part 2: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 8 Frontline Forum Part 3: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 8 Frontline Forum Part 3: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 9 Frontline Forum Part 4: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 9 Frontline Forum Part 4: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 10 Frontline Forum Part 5: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 10 Frontline Forum Part 5: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 11 Expert Perspective on the Care of Patients with Atopic Dermatitis

EP. 11 Expert Perspective on the Care of Patients with Atopic Dermatitis

EP. 12 Role of Disease Severity in Topical vs Systemic AD Treatment

EP. 12 Role of Disease Severity in Topical vs Systemic AD Treatment

EP. 13 Efficacy and Safety of JAK inhibitors for AD

EP. 13 Efficacy and Safety of JAK inhibitors for AD

EP. 14 Optimizing Patient Outcomes with JAK Inhibitors

EP. 14 Optimizing Patient Outcomes with JAK Inhibitors

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population

Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC

First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA

Phase 2 Nemolizumab Trial Opens for CPUO

Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1

© 2025 MJH Life Sciences^®

All rights reserved.